The CNRIP1 Knockout Raji Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the gene encoding cannabinoid receptor interacting protein 1 (CNRIP1) has been disrupted. This polyclonal knockout pool, derived from the Raji B-lymphocyte cell line, serves as a genetically defined loss-of-function model for investigating CNRIP1-dependent signaling in a human B-cell context.
Raji is an Epstein-Barr virus (EBV)-positive lymphoblastoid cell line originally established from a Burkitt lymphoma patient. As a model B lymphocyte, Raji cells retain key features of antigen presentation and antibody production, making them a widely employed system for studying B-cell biology, lymphomagenesis, and immune signaling. The EBV-driven background also provides a context for exploring viral oncogenesis and its interplay with host cell signaling networks.
CNRIP1 functions as a modulator of cannabinoid receptor 1 (CB1, encoded by CNR1) by binding its intracellular C-terminal domain, thereby suppressing constitutive receptor activity and shaping agonist-induced Gi/o-mediated signaling. Through its interaction with G-protein alpha subunits GNAI1 and GNAO1, and potentially ??-arrestin, CNRIP1 influences downstream cascades including adenylyl cyclase (ADCY1)-mediated cAMP production, MAPK/ERK signaling via MAPK1 (ERK2), and the PI3K/AKT pathway through AKT1. The endocannabinoids anandamide and 2-arachidonoylglycerol, as well as synthetic cannabinoid agonists and cellular stress, serve as upstream regulators that engage this signaling module, ultimately affecting cAMP levels and the activity of protein kinase A (PRKACA), ERK, and AKT.
In the Raji B-cell lymphoma context, disruption of CNRIP1 allows dissection of how cannabinoid receptor signaling intersects with pathways governing B-cell survival, proliferation, and immune function. Given that MAPK1 and AKT1 are critical nodes for cell growth and apoptosis, this knockout model enables investigation of CNRIP1 as a regulator of these oncogenic pathways in EBV-driven lymphomagenesis. Furthermore, the polyclonal knockout population preserves the heterogeneity of B-cell responses, making it suitable for assessing the collective impact of CNRIP1 loss on signal transduction and cellular phenotypes.
Researchers can employ this polyclonal knockout population for functional interrogation of CNRIP1 in B-cell lymphoma, using assays such as Western blotting for CNRIP1, CB1, and phospho-ERK (MAPK1), RT-qPCR for transcript analysis, flow cytometry to detect CB1 surface expression and phospho-ERK, or cAMP GloSensor assays to monitor Gi/o-coupled signaling dynamics. Additionally, cell viability (MTT) and apoptosis (Annexin V/PI staining) assays facilitate assessment of CNRIP1??s role in proliferation and survival, while coculture or neuroimmune models can explore GPCR crosstalk with B-cell receptor signaling. For further technical details, please contact Ascent Research.
